Ovarian Cancer

>

Latest News

Investigators of the OVATION-2 trial assessed IMNN-001, a novel IL-2 gene therapy, in patients with newly diagnosed epithelial ovarian cancer.
PFS, OS Numerically Improve Via IMNN-001 Combo in Epithelial Ovarian Cancer

June 4th 2025

Investigators of the OVATION-2 trial assessed IMNN-001, a novel IL-2 gene therapy, in patients with newly diagnosed epithelial ovarian cancer.

Data from the ROSELLA trial may support relacorilant plus nab-paclitaxel as a new standard in this ovarian cancer population.
Relacorilant and Nab-Paclitaxel Significantly Extend PFS in Ovarian Cancer

June 2nd 2025

Dostarlimab/Chemo, Maintenance Niraparib Show Modest Improvements in Ovarian Cancer
Dostarlimab/Chemo, Maintenance Niraparib Show Modest Improvements in Ovarian Cancer

June 2nd 2025

The safety profile of pembrolizumab in the KEYNOTE-B96 study was comparable with prior reports of the agent, and investigators observed no new safety signals.
Pembrolizumab Combo Extends PFS in Platinum-Resistant Ovarian Cancer

May 15th 2025

Findings from the phase 2 RAMP 201 trial support the FDA approval of avutometinib plus defactinib in low-grade serous ovarian cancer.
FDA Grants Accelerated Approval to Avutometinib/Defactinib in KRAS+ LGSOC

May 8th 2025

Video Series
Video Interviews
Podcasts
Low grade serous ovarian cancer, a rare epithelial ovarian cancer subtype, requires differentiated treatment from its high-grade counterpart.
Latest CME Events & Activities

Medical Crossfire®: Expert Perspectives on Targeting c-Met Overexpression and 𝘔𝘌𝘛 Genomic Alterations in NSCLC – Unveiling the Complexities of 𝘔𝘌𝘛 Dysregulation

View More

Tumor Board: Expert Insights on Managing Classical 𝘌𝘎𝘍𝘙 Mutations, 𝘌𝘎𝘍𝘙 Exon 20 Insertions, and Atypical 𝘌𝘎𝘍𝘙 Mutations in Metastatic NSCLC

View More

Medical Crossfire®: Harnessing the Power of Modern Therapies in Newly Diagnosed Multiple Myeloma

View More

Cases and Conversations™: Sorting Through the Expanding Treatment Options for Patients with Relapsed/Refractory Multiple Myeloma

View More

Evolving Treatment Strategies in Pancreatic Cancer: Current Standards, Emerging Targets, and the Role of Molecular Testing

View More

Cases & Conversations™: Transforming AML Care—Precision Strategies, Evolving Therapies, and Clinical Insights

View More

PER Tumor Board®: Applying Recent Advances to Transform the Treatment Paradigm in SCLC—Expert Perspectives on New Approvals and Emerging Strategies

View More

Medical Crossfire®: Precision Medicine in Glioma Treatment—Integration of Molecular Profiling to Inform Targeted Therapies

View More

Medical Crossfire®: Integrating Next-Generation Endocrine Targeting Therapies to Improve Outcomes for Patients With HR+/HER2- Breast Cancer

View More

GI Tumor Board—Applying Recent Advances in Biomarker Testing and Treatment in Metastatic Colorectal Cancer

View More

Medical Crossfire®: Improving Patient Outcomes in Myeloproliferative Neoplasms With Novel Therapeutic Approaches

View More

Fighting Disparities and Saving Lives: An Exploration of Challenges and Solutions in Cancer Care

View More

26th Annual International Lung Cancer Congress®

July 25-26, 2025

Register Now!

Community Practice Connections™: Selecting and Sequencing Therapy for Patients with DLBCL in an Era of Expanding Options

View More

8th Annual Live Medical Crossfire®: Hematologic Malignancies

View More

Community Practice Connections™: 14th Asia-Pacific Primary Liver Cancer Expert Meeting

View More

Biomarkers in Diffuse Large B-Cell Lymphoma: Empowering Treatment Decisions to Improve Outcomes

View More

Contextualizing Advances in Relapse Refractory DLBCL: Navigating Biomarkers, Emerging Data, and Adverse Event Management to Transform Patient Care

View More

Burst CME™: Tackling Adverse Events With Targeted Therapies for Diffuse B-Cell Lymphoma

View More

Treating Relapsed/Refractory Diffuse Large B-Cell Lymphoma: Current Options and Emerging Approaches

View More

BURST Expert Illustrations and Commentaries™: Exploring the Mechanistic Rationale for CSF-1R– Directed Treatment in Chronic GVHD

View More

Community Practice Connections™: 23rd Annual International Congress on the Future of Breast Cancer West

View More

(CME) Optimizing Management of Ocular Toxicity in Cancer Patients: The Role of Ophthalmologists in the Spectrum of Care

View More

(COPE) Optimizing Management of Ocular Toxicity in Cancer Patients: The Role of Ophthalmologists in the Spectrum of Care

View More

20th Annual New York Lung Cancers Symposium®

November 15, 2025

Register Now!

PER® Liver Cancer Tumor Board: How Do Evolving Data for Immune-Based Strategies in Resectable and Unresectable HCC Impact Multidisciplinary Patient Management Today… and Tomorrow?

View More

Community Practice Connections™: 6th Annual Precision Medicine Symposium – An Illustrated Tumor Board

View More

Advances In™: Taking R/R B-Cell ALL Management to the Next Level With New CAR T Approval

View More

Navigating Low-Grade Serous Ovarian Cancer – Enhancing Diagnosis, Sequencing Therapy, and Contextualizing Novel Advances

View More

Cases & Conversations™: Integrating Novel Approaches to Treatment in First-line ALK+ mNSCLC – Enhancing Patient Outcomes with Real World Multidisciplinary Strategies

View More

More News